Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis

Unresectable glioblastomas with severe neurological impairment at diagnosis have a poor prognosis. The conventional approach using a temozolomide-based chemoradiotherapy has limited efficiency on patients in the RTOG RPA V–VI classes. The activity of the antiangiogenic monoclonal antibody bevacizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bihan, Celina, Foscolo, Sylvain, Boone, Mathieu, Blonski, Marie, Coutte, Alexandre, Darlix, Amélie, Beauchesne, Patrick, Lefranc, Michel, Lorgis, Veronique, Taillandier, Luc, Chauffert, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
September, 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492967/
https://www.ncbi.nlm.nih.gov/pubmed/23139667
http://dx.doi.org/10.1159/000343139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492967/
https://www.ncbi.nlm.nih.gov/pubmed/23139667
http://dx.doi.org/10.1159/000343139

Ejemplares similares